- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01525667
Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty
A Phase I/II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
One of the main problems when performing THA via the standard transgluteal approach is the necessary injury of the gluteus medius muscle. The consecutive decrease of contractile muscle substance and the substitution by scar tissue leads to functional deficits of the pelvic-stabilizing musculature with an insufficiency limp in a large number of patients. In the long run the lack of musculature leads to a decrease in bone substance at the insertion sites of the gluteal muscles of the proximal femur. The present study has the aim of establishing a new therapy for iatrogenic gluteal muscle damage. The hypothesis of the present proposal is that intra-muscular (IM) injection of PLX-PAD into the iatrogenically injured gluteus medius muscle after THA results in an improved regeneration of the skeletal muscle tissue and consecutively in an improved functional outcome.
Subjects will be assigned to receive one of the two targeted doses of PLX-PAD or placebo. On the treatment day, after suturing the gluteus medius muscle PLX-PAD or placebo will be applied directly to the site of laceration.
Patients will be followed up for efficacy assessment up to week 26 and for safety assessment (Adverse events, vital signs, ECG, routinf lab and immunological testing) up to week 52 after THA. Patients will be phoned at week 104 in order to inquire about the occurence of new cancer.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- Charité Universitätsmedizin Berlin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects between 50 to 75 years of age
- Scheduled THA
- ASA Score ≤ 3
- Signed written informed consent
Exclusion Criteria:
- Muscle diseases
- Severe neurological diseases
- Opioid long term medication
- Pain chronification > stadium II of Gerbershagen
- Immunosuppression due to illness or medication
- Ankylosing spondylitis
- History of ectopic bone formation of any localisation
- Exclusion criteria for MRI (pace maker, defibrillator, ferromagnetic intracerebral clips)
- Uncontrolled hypertension (defined as diastolic blood pressure > 100 mmHg or systolic blood pressure > 200 mmHg during screening)
- Life-threatening ventricular arrhythmia or unstable angina - characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, and prolonged
- ST segment elevation myocardial infarction and/or TIA/CVA within three (3) months prior to enrollment. Subjects with severe congestive heart failure symptoms (i.e. NYHA Stage IV)
- Subject has malignancy undergoing treatment including chemotherapy, radiotherapy or immunotherapy
- Body Mass Index (BMI) of 35 Kg/m2 or greater
- Known allergies to protein products (horse or bovine serum, or porcine trypsin) used in the cell production process
- Known HIV, syphilis at time of screening
- Known active Hepatitis B, or Hepatitis C infection at the time of screening
- Pregnant or breast-feeding women or women of childbearing potential not protected by an effective contraceptive method of birth control (defined as pearl index < 1)
- In the opinion of the investigator, the subject is unsuitable for cellular therapy
- Subject is currently enrolled in, or has not yet completed a period of at least 30 days since ending other investigational device or drug trial(s)
- Subjects who are legally detained in an official institute
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 150M PLX-PAD
Single course, multiple IM injections
|
Single course, multiple IM injections
|
Experimental: 300M PLX-PAD
Single course, multiple IM injections
|
Single course, multiple IM injections
|
Placebo Comparator: Placebo
Single course, multiple IM injections
|
Single course, multiple IM injections
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Day 0 to Week 26 in the Maximal Voluntary Isometric Contraction (MVIC) Moment of the Injured Side to Assess Gluteus Medius Strength.
Time Frame: Day 0 to Week 26
|
Change from Visit 2 (Day 0) to Week 26 in the maximal voluntary isometric contraction (MVIC) moment of the injured side as measured by isometric dynamometry to assess Gluteus Medius force strength.
|
Day 0 to Week 26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Day 0 to Week 26 in Muscle Volume.
Time Frame: Day 0 to Week 26
|
Change from Visit 2 (Day 0) to Week 26 in Muscle Volume as Measured by MRI.
|
Day 0 to Week 26
|
Change From Day 1 to Week 12 in Mean Fiber Diameter.
Time Frame: Day 1 to Week 12
|
Change from Visit 3 (Day 1) to Week 12 in Mean Fiber Diameter as Measured by Muscle Biopsy.
|
Day 1 to Week 12
|
Change From Day 0 to Week 26 in the Ratio of Injured to Contralateral Pelvic Shift .
Time Frame: Day 0 to Week 26
|
Change from Visit 2 (Day 0) to Week 26 in the Ratio of Injured to Contralateral Pelvic Shift as Measured by Gait Analysis
|
Day 0 to Week 26
|
Change From Day 0 to Week 26 in the Visual Analog Scale (VAS) Pain Score.
Time Frame: Day 0 to Week 26
|
Visual Analog Scale (VAS) Pain Score ranges from 0 mm (no pain) to 100 mm (worse possible pain)
|
Day 0 to Week 26
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Carsten Perka, MD, Charité Universitätsmedizin Berlin, Dept. Of Orthopedic Surgery, Charitéplatz 1, 10117 Berlin, Germany
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PLX-PAD 1301-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Total Hip Arthroplasty
-
DePuy OrthopaedicsJohnson & Johnson Health and Wellness Solutions, Inc.TerminatedTotal Knee Arthroplasty; Total Hip ArthroplastyUnited States
-
DePuy OrthopaedicsJohnson & Johnson Health and Wellness Solutions, Inc.TerminatedTotal Knee Arthroplasty; Total Hip ArthroplastyUnited States
-
National Taiwan University HospitalUnknownTotal Hip Replacement | Total Hip ArthroplastyTaiwan
-
Northern Orthopaedic Division, DenmarkCompletedTotal Knee Arthroplasty | Total Hip ArthroplastyDenmark
-
Ortho Development CorporationOregon Health and Science UniversityEnrolling by invitationTotal Hip Replacement | Total Hip ArthroplastyUnited States
-
James A. KeeneyRecruitingPrimary Total Hip Arthroplasty | Primary Total Knee ArthroplastyUnited States
-
Musgrave Park HospitalBelfast Health and Social Care Trust; Queen's University, Belfast; Belfast Arthroplasty...CompletedTotal Hip Replacement | Total Hip Arthroplasty | THA | THRUnited Kingdom
-
Permedica spaNot yet recruitingTotal Hip ArthroplastyItaly
-
ExactechRecruiting
-
Mauro CrestaniRecruitingTotal Hip ArthroplastyItaly
Clinical Trials on 150M PLX-PAD
-
Pluristem Ltd.TerminatedCOVID | ARDSIsrael, Germany
-
Pluristem Ltd.CompletedPeripheral Vascular Disease | Peripheral Artery Disease | Critical Limb IschemiaUnited States
-
Pluristem Ltd.UnknownCritical Limb Ischemia (CLI)Germany, United Kingdom, Hungary, United States, Bulgaria, Czechia, Israel, North Macedonia, Poland
-
WideTrial, Inc.AvailableCritical Limb Ischemia (CLI)
-
Pluristem Ltd.CompletedIntermittent Claudication | Peripheral Artery DiseaseUnited States, Germany, Korea, Republic of, Israel
-
Pluristem Ltd.CompletedPeripheral Vascular Disease | Peripheral Artery Disease | Critical Limb IschemiaGermany
-
United TherapeuticsTerminatedPulmonary Arterial HypertensionAustralia
-
Pluristem Ltd.AvailableCritical Limb Ischemia (CLI)United States
-
Pluristem Ltd.TerminatedCOVID | ARDSUnited States
-
Pluristem Ltd.CompletedHip FractureUnited Kingdom, Bulgaria, Germany, United States, Israel